<DOC>
	<DOCNO>NCT02545868</DOCNO>
	<brief_summary>This multicenter , randomize , open-label study evaluate immune response vaccine ( tetanus toxoid [ TT ] , 23-valent pneumococcal polysaccharide vaccine [ 23-PPV ] , influenza vaccine , keyhole limpet hemocyanin [ KLH ] ) administration dose ocrelizumab ( OCR ) participant relapse multiple sclerosis ( RMS ) .</brief_summary>
	<brief_title>A Study Evaluate Effects Ocrelizumab Immune Responses In Participants With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis RMS accordance revise McDonald criterion Received least 1 previous immunization TT tetanus diphtheria ( DT/Td ) tetanus , diphtheria , acellular pertussis ( DTaP/Tdap ) Expanded disability status scale ( EDSS ) baseline 0 5.5 point , inclusive For sexually active participant reproductive potential , use reliable mean contraception Contraindications intolerance oral intravenous corticosteroid , include intravenous methylprednisolone , accord country label Known presence neurologic disorder Treatment investigational agent within 24 week screen 5 halflives investigational drug , whichever longer , treatment experimental procedure multiple sclerosis ( MS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>